An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Metastatic Breast Cancer (CRONOS 2)
NCT01277133 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 83
Last updated 2016-11-02
Summary
This single arm, prospective, observational study will assess the correlation between the time from start of chemotherapy to the start of Avastin (bevacizumab) treatment with progression-free survival in patients with previously untreated metastatic breast cancer. Patients will be followed for up to 12 months after progressive disease occurs.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Trials · Hoffmann-La Roche
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-06-30
- Primary Completion
- 2015-10-31
- Completion
- 2015-10-31
Countries
- Romania
Study Locations
More Related Trials
-
Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer
NCT00517361 ·Status: TERMINATED ·Phase: PHASE2
-
Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer
NCT01978977 ·Status: COMPLETED
-
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
NCT00929240 ·Status: COMPLETED ·Phase: PHASE3
-
Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer
NCT01745757 ·Status: COMPLETED
-
Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.
NCT00240071 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer
NCT00333775 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
NCT00121836 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer
NCT00846027 ·Status: COMPLETED ·Phase: PHASE2
-
AVAREG Study: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer
NCT01777932 ·Status: COMPLETED
-
First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC
NCT04408118 ·Status: COMPLETED ·Phase: PHASE2
-
Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer
NCT01663727 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
NCT00476827 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer
NCT00845910 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer
NCT00964704 ·Status: WITHDRAWN ·Phase: PHASE2
-
Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer
NCT01195298 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients
NCT00820547 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer
NCT01200212 ·Status: TERMINATED ·Phase: PHASE3
-
1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
NCT00493636 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer
NCT00618826 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
NCT00391092 ·Status: COMPLETED ·Phase: PHASE3
-
Epidemiology and Management of Metastatic Breast Cancer
NCT01711502 ·Status: COMPLETED
-
A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study
NCT00096967 ·Status: COMPLETED ·Phase: PHASE3
-
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
NCT00654836 ·Status: COMPLETED ·Phase: PHASE2
-
Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer
NCT00694200 ·Status: TERMINATED ·Phase: PHASE2
-
Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis
NCT01373710 ·Status: COMPLETED ·Phase: PHASE1/PHASE2